Vancouver, British Columbia and Minneapolis, Minnesota (Newsfile Corp. - May 13, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) today announced that it will sponsor a symposium
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
Neovasc Announces First Patient Enrollment in COSIMA Trial
NeovascMay 10, 2021 GMT
VANCOUVER and MINNEAPOLIS - (NewMediaWire) - May 10, 2021 - Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronarySInus Reducer for the Treatment of Refractory MicrovascularAngina (“COSIMA”) trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who suffers from severe Canadian Cardiovascular Society (“CCS”) Class IV angina on a daily basis despite optimal medical treatment. The study is being led by Prof. Tommaso Gori, M.D., Ph.D., University Medical Center, Mainz, Germany.
Neovasc Inc.: Neovasc Announces First Patient Enrollment in COSIMA Trial
COronary
Microvascular
Angina ( COSIMA ) trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who suffers from severe Canadian Cardiovascular Society ( CCS ) Class IV angina on a daily basis despite optimal medical treatment. The study is being led by Prof. Tommaso Gori, M.D., Ph.D., University Medical Center, Mainz, Germany.
COSIMA is a randomized controlled trial, supported by Neovasc, investigating the Neovasc Reducer ( Reducer ) for the treatment of Microvascular Angina. The study will enroll up to 144 patients across multiple centers in Germany. The primary endpoint of the study is change in CCS angina class, a measure of chest pain severity and limitation, by two or more classes. Patients enrolled in the trial will be randomized to one of two groups: the treatment arm will receive the Reducer and continue with their optimized medications; the cont